在医药行业转型升级的关键期，华润双鹤正以清晰的战略布局书写高质量发展答卷。华润双鹤董事长陆文超日前在接受中国证券报记者专访时表示，华润 双鹤的发展始终与国家战略、民众需求同频共振，通过深耕集采锤炼全价值链硬实力，以"处方药龙头打造+合成生物突破"双轮驱动构建核心竞争力，更 依托国际化布局拓宽发展边界，为企业长远发展注入强劲动能。 华润双鹤总部大楼 华润双鹤供图 构建全价值链硬实力 "华润双鹤的发展轨迹，始终与国家战略部署、民众健康需求紧密相连。"陆文超表示，从地方药企到全国性集团，从规模扩张到高质量发展，公司每一次 转型都紧扣时代脉搏，在顺应变革中实现可持续发展。"如今华润双鹤已构建起覆盖抗感染、慢病、专科等多个领域的产品体系，既在市场变化中保持稳 健活力，也为守护国民健康持续发力。" 国家药品集中带量采购政策的落地，成为华润双鹤锤炼核心能力的重要契机。陆文超表示，政策推出以来，公司便确立了积极拥抱的战略方向，旨在通过 深度参与集采获取政策红利。截至目前，公司累计有近60个产品在国家集采中中标，超过70%的产品在省级及联盟集采中中选。 "参与集采，是我们构建全价值链低成本能力的'牛鼻子'和核心纽带。"陆文超说 ...

● 本报记者 傅苏颖 在医药行业转型升级的关键期，华润双鹤正以清晰的战略布局书写高质量发展答卷。华润双鹤董事长陆 文超日前在接受中国证券报记者专访时表示，华润双鹤的发展始终与国家战略、民众需求同频共振，通 过深耕集采锤炼全价值链硬实力，以"处方药龙头打造+合成生物突破"双轮驱动构建核心竞争力，更依 托国际化布局拓宽发展边界，为企业长远发展注入强劲动能。 构建全价值链硬实力 "华润双鹤的发展轨迹，始终与国家战略部署、民众健康需求紧密相连。"陆文超表示，从地方药企到全 国性集团，从规模扩张到高质量发展，公司每一次转型都紧扣时代脉搏，在顺应变革中实现可持续发 展。"如今华润双鹤已构建起覆盖抗感染、慢病、专科等多个领域的产品体系，既在市场变化中保持稳 健活力，也为守护国民健康持续发力。" 国家药品集中带量采购政策的落地，成为华润双鹤锤炼核心能力的重要契机。陆文超表示，政策推出以 来，公司便确立了积极拥抱的战略方向，旨在通过深度参与集采获取政策红利。截至目前，公司累计有 近60个产品在国家集采中中标，超过70%的产品在省级及联盟集采中中选。 "参与集采，是我们构建全价值链低成本能力的'牛鼻子'和核心纽带。"陆文超说，参 ...

Core Viewpoint - The management of Zhongguancun has demonstrated strong confidence in the company's future development and long-term investment value through consistent stock purchases since 2015, with no sell-offs over the past decade [1][2]. Group 1: Management Shareholding - The management team, including the chairman and president, has increased their shareholding multiple times since 2015, with the latest increase planned for February 2024, reflecting their commitment to the company [1]. - As of the mid-2025 report, key management members hold significant shares: 190,000 shares by the chairman, 100,000 by the CFO, and smaller amounts by other executives, all without any reductions in their holdings over ten years [1]. Group 2: Business Strategy and Performance - Since 2015, the company has focused on the "pharmaceutical and health industry" as its core strategy, leading to a steady increase in revenue from its pharmaceutical business [2]. - In 2021, the company further concentrated on its pharmaceutical main business, aiming to build an "innovative pharmaceutical industry group," and in July 2024, it refined its strategy to become a leading service provider in the health industry [2]. Group 3: Product Development and Market Position - The company is actively enhancing its product matrix in the controlled substance sector, with recent approval of a generic drug, which is the first of its kind in the domestic market, expected to improve its competitive edge [3]. - The introduction of new products, such as the hydromorphone injection and the development of methylphenidate, alongside the expansion of its light-asset model in the elderly care sector, positions the company for sustainable growth and value creation for investors [3].